DTC (DTC) News
Follow DTC (DTC) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 7 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Defence Therapeutics Inc. (DTC) Adds Sherry Aulin to Board, Grants 400K Options
Defence Therapeutics Inc. appointed finance executive Sherry Aulin to its Board of Directors and Audit Committee, and granted her 400,000 options at $0.40, half vesting immediately and half in one year.Material DetailsCo
NEWS | Sep 29, 2026, 07:18 AM UTC
L
Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors
Montreal, Quebec--(. - September 29, 2026) - Defence Therapeutics Inc. CSE:DTC (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncolog
NEWS | Sep 29, 2026, 07:18 AM UTC
L
Defence Therapeutics Inc. (DTC) Grants 7.0M Performance RSUs; Board Change
Defence Therapeutics granted 7,000,000 performance-based RSUs to its CEO and Executive Chairman and moved Dr. Svetlana Selivanova from the Board to the Scientific Advisory Board to support radiopharma programs.Material D
NEWS | Sep 28, 2026, 09:08 PM UTC
L
Defence Therapeutics Provides Corporate Update as Company Executes on Strategic Priorities
Montreal, Quebec--(. - September 28, 2026) - Defence Therapeutics Inc. CSE:DTC (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology
NEWS | Sep 28, 2026, 09:01 PM UTC
L
Defence Therapeutics CEO letter outlines strategic priorities
Defence Therapeutics said its CEO highlighted recent progress and outlined strategic priorities in a letter to shareholders, noting its next-generation precision oncology therapeutics development using proprietary Accum
EQUITY | Sep 08, 2026, 07:16 AM UTC
L
Defence Therapeutics Provides Updates on Sharing Agreement
Montreal, Quebec--(. - September 4, 2026) - Defence Therapeutics Inc. CSE:DTC (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is
EQUITY | Sep 04, 2026, 10:06 PM UTC
L
Defence Therapeutics expands radiopharmaceutical development strategy
Defence Therapeutics says it is expanding its radiopharmaceutical development strategy with alpha and beta-emitter programs.
EQUITY | Aug 31, 2026, 07:16 AM UTC